Screening for adrenal-endocrine hypertension: Overview of accuracy and cost-effectiveness

Research output: Contribution to journalReview articlepeer-review

23 Scopus citations


Formal studies have not been performed to assess the cost-effectiveness of screening strategies for endocrine causes of hypertension. However, an understanding of the diagnostic accuracy of available screening tests and the clinical settings where disease identification will lead to improved health outcomes form the basis for a cost-effective strategy. Primary aldosteronism screening should be selective and restricted to settings where knowledge of the diagnosis has the greatest chance of improving health outcomes. Pheochromocytoma is rare; however, because it is a potentially fatal disease, screening strategies should err on the side of not missing the diagnosis, especially in high-risk clinical settings.

Original languageEnglish (US)
Pages (from-to)279-294
Number of pages16
JournalEndocrinology and Metabolism Clinics of North America
Issue number2
StatePublished - Jun 2011


  • Adrenal
  • Diagnostic accuracy
  • Screening
  • Secondary hypertension

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism
  • Endocrinology


Dive into the research topics of 'Screening for adrenal-endocrine hypertension: Overview of accuracy and cost-effectiveness'. Together they form a unique fingerprint.

Cite this